Endometriosis – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Endometriosis is defined as the abnormal growth of endometrial tissue, which is similar to that which lines the interior of the uterus but occurs outside of the uterus. During menstruation, endometrial tissue is shed. Endometrial implants are areas of endometrial tissue found in ectopic sites. These lesions are most generally found on the ovaries, the Fallopian Tubes, the uterine surface, the bowel, and the pelvic cavity membrane lining (i.e., the peritoneum). They are less frequently found in the vaginal, cervix, and bladder. Endometriosis can occur outside the pelvis on rare occasions. While endometrial implants can cause complications, they are usually harmless. Endometriosis is classified into four stages: I (mild), II (mild), III (moderate), and IV (severe) based on the number, location, and depth of implants, as well as the presence of filmy or dense adhesions. Another staging system is based primarily on the company and severity of pelvic pain. However, a more reliable staging method is being sought because intra-observer and inter-observer variability are high in the staging systems.

The prevalence of cases of Endometriosis ranges from 350 to 378 cases per 100,000 population in the USA.

 

The competitive landscape of Endometriosis includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Endometriosis across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Endometriosis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Endometriosis – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          V-Endo Immunitor LLC  Phase 2

2          Leuprolide         Enteris BioPharma Inc.  Phase 2

3          BGS649            Mereo BioPharma         Phase 2

4          BOL-DP-o-08    Breath of Life International Pharma Ltd   Phase 2

5          linzagolix tablet ObsEva SA       Phase 3

6          Quinagolide       Ferring Pharmaceuticals            Phase 2

7          Relugolix           Myovant Sciences GmbH          Phase 3

8          Elagolix AbbVie  Phase 3

9          Vaginal Danazol            Viramal Limited Phase 2

10        BAY1817080     Bayer   Phase 1

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033